Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/9030
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mallinckrodt, Craig H. | - |
dc.contributor.author | Sanger, Todd M. | - |
dc.contributor.author | Dubé, Sanjay | - |
dc.contributor.author | DeBrota, David J. | - |
dc.contributor.author | MOLENBERGHS, Geert | - |
dc.contributor.author | Carroll, Raymond J. | - |
dc.contributor.author | Potter, William Z. | - |
dc.contributor.author | Tollefson, Gary D. | - |
dc.date.accessioned | 2008-12-18T07:44:57Z | - |
dc.date.available | 2008-12-18T07:44:57Z | - |
dc.date.issued | 2003 | - |
dc.identifier.citation | BIOLOGICAL PSYCHIATRY, 53(8), p. 754-760. | - |
dc.identifier.issn | 0006-3223 | - |
dc.identifier.uri | http://hdl.handle.net/1942/9030 | - |
dc.description.abstract | Treatment effects are often evaluated by comparing change over time in outcome measures; however, valid analyses of longitudinal data can be problematic, particularly if some data are missing. For decades, the last observation carried forward (LOCF) approach has been a common method of handling missing data. Considerable advances in statistical methodology and our ability to implement those methods have been made in recent years. Thus, it is appropriate to reconsider analytic approaches for longitudinal data. This review examines the following from a clinical perspective: I) the characteristics of missing data that influence analytic choices; 2) the attributes of common methods of handling missing data; and 3) the use of the data characteristics and the attributes of the various methods, along with empirical evidence, to develop a robust approach for the analysis and interpretation of data from longitudinal clinical trials. We propose that, in many settings, the primary efficacy analysis should use a repeated measures, likelihood-based, mixed-effects modeling approach, with LOCF used as a secondary, composite measure of efficacy, safety, and tolerability. We illustrate how repeated-measures analyses can be used to enhance decision-making, and we review the caveats that remain regarding the use of LOCF as a composite measure. | - |
dc.description.sponsorship | This work was sponsored by Eli Lilly and Company. The authors thank Ms. Renee Bacall for her editorial assistance and the reviewers for their detailed comments. Their contributions greatly enhanced the quality of this manuscript. Aspects of this work were presented at the conference, “Difficult-toTreat Depression,” held April 21–22, 2002 in San Francisco, California. The conference was sponsored by the Society of Biological Psychiatry through an unrestricted grant provided by Eli Lilly and Company. | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.relation.ispartofseries | Biological Psychiatry | - |
dc.rights | © 2003 Society of Biological Psychiatry | - |
dc.subject.other | missing data; longitudinal data; mixed-effects models; repeated measures; depression | - |
dc.subject.other | missing data; longitudinal data; mixed-effects models; repeated measures; depression | - |
dc.title | Assessing and interpreting treatment effects in longitudinal clinical trials with missing data | - |
dc.type | Proceedings Paper | - |
local.bibliographicCitation.conferencedate | 21-22/04/2002 | - |
local.bibliographicCitation.conferencename | Conference on Difficult-to-Treat Depression | - |
local.bibliographicCitation.conferenceplace | San Francisco (CA), USA | - |
dc.identifier.epage | 760 | - |
dc.identifier.issue | 8 | - |
dc.identifier.spage | 754 | - |
dc.identifier.volume | 53 | - |
local.format.pages | 7 | - |
local.bibliographicCitation.jcat | C1 | - |
dc.description.notes | Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA. Univ Pittsburgh, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. Limburgs Univ Ctr, Ctr Stat, Diepenbeek, Belgium. Texas A&M Univ, Dept Stat, College Stn, TX 77843 USA. | - |
local.publisher.place | New York, NY, USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Proceedings Paper | - |
dc.bibliographicCitation.oldjcat | C1 | - |
dc.identifier.doi | 10.1016/S0006-3223(03)01867-X | - |
dc.identifier.isi | 000182360400012 | - |
dc.identifier.url | https://www.academia.edu/8393353/Assessing_and_interpreting_treatment_effects_in_longitudinal_clinical_trials_with_missing_data | - |
local.bibliographicCitation.btitle | BIOLOGICAL PSYCHIATRY | - |
item.accessRights | Restricted Access | - |
item.contributor | Mallinckrodt, Craig H. | - |
item.contributor | Sanger, Todd M. | - |
item.contributor | Dubé, Sanjay | - |
item.contributor | DeBrota, David J. | - |
item.contributor | MOLENBERGHS, Geert | - |
item.contributor | Carroll, Raymond J. | - |
item.contributor | Potter, William Z. | - |
item.contributor | Tollefson, Gary D. | - |
item.fullcitation | Mallinckrodt, Craig H.; Sanger, Todd M.; Dubé, Sanjay; DeBrota, David J.; MOLENBERGHS, Geert; Carroll, Raymond J.; Potter, William Z. & Tollefson, Gary D. (2003) Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. In: BIOLOGICAL PSYCHIATRY, 53(8), p. 754-760.. | - |
item.validation | ecoom 2004 | - |
item.fulltext | With Fulltext | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
molg04.pdf Restricted Access | Published version | 61.83 kB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
187
checked on Oct 12, 2024
Page view(s)
52
checked on Sep 7, 2022
Download(s)
40
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.